<?xml version='1.0' encoding='UTF-8' standalone='no'?>
<rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:bqbiol="http://biomodels.net/biology-qualifiers/" xmlns:collex="http://www.collex.org/schema#" xmlns:bqmodel="http://biomodels.net/model-qualifiers/" xmlns:scoro="http://purl.org/spar/scoro/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:biomodel="http://biomodels.net/model-qualifiers/">
  <rdf:Description rdf:about="http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex">
    <dc:title>Flynn, Green, Pedley, Boxer, Dearling, Watson, Boden, Begent, 2002</dc:title>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex">
    <prism:keyword>immunology</prism:keyword>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex">
    <prism:keyword>tumour dynamics</prism:keyword>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex">
    <prism:keyword>antibody kinetics</prism:keyword>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex">
    <prism:keyword>radioimmunotherapy</prism:keyword>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex">
    <dc:description>#### Model Status



 This is the original unchecked version of the model imported from the previous
 CellML model repository, 24-Jan-2006.
 


#### Model Structure



Radioimmunotherapy (RIT) is a treatment for cancer which combines radiation and immune therapy using monoclonal antibodies. RIT uses a radioactive material attached to specially designed antibodies to locate cancer within the body. Antibodies are defense proteins which are naturally produced by the body's immune system in order to fight infections caused by bacteria and other foreign pathogens. The antibodies used in RIT are monoclonal antibodies (MAbs) which are developed in the laboratory in order to recognise marker molecules on the surface of tumor cells. These antibodies are then modified to bind the radioactive metal Yttrium-90, which delivers high levels of local radiation to the tumour and subsequently destroys it.




The effectiveness of RIT is known to depend on at least six factors, including:



* the totla absorbed dose and pattern of delivery;
* radiosensitivity;
* rate of repair of sublethal damage;
* ongoing cancer proliferation during treatment;
* tumour heterogeneity; and
* tumour size.



Therefore no single parameter is a good indicator of how effective the RIT has been. Instead, several factors have to be simulataneously considered in order to get a more accurate characterisation of the biological effect.




The aim of this study by Flynn *et al.* was to develop a mathematical model that would relate the absorbed dose and its pattern of delivery to tumour response by incorporating information on each of the six influencing factors (see 
 the figure
 below). The mathemtical model was then used to optimise therapeutic efficacy in mice by matching the antibody and radionuclide characteristics while ensuring recoverable marrow toxicity. 




The complete original paper reference is cited below:




[A Model-Based Approach for the Optimization of Radioimmunotherapy through Antibody Design and Radionuclide Selection](http://www3.interscience.wiley.com/cgi-bin/abstract/90511815/ABSTRACT), Aiden A. Flynn, Alan J. Green, R. Barbara Pedley, Geoffrey M. Boxer, Jason Dearling, Rebecca Watson, Robert Boden, and Richard H. J. Begent, 2002, [*Cancer*](http://www3.interscience.wiley.com/cgi-bin/jhome/28741), 94, 1249-1257. ([Full text (HTML)](http://www3.interscience.wiley.com/cgi-bin/fulltext/90511815/HTMLSTART) and [PDF](http://www3.interscience.wiley.com/cgi-bin/fulltext/90511815/PDFSTART) versions of the article are available to subscribers on the *Cancer* website.) [PubMed ID: 11877753](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11877753&amp;dopt=Abstract)</dc:description>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex">
    <collex:thumbnail rdf:resource="http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex/flynn_2002.png">http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex/flynn_2002.png</collex:thumbnail>
  </rdf:Description>
  <rdf:Description rdf:about="local:00001">
    <rdfs:label>Aiden A. Flynn</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00001">
    <foaf:name>Aiden A. Flynn</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex">
    <dc:creator rdf:resource="local:00001">local:00001</dc:creator>
  </rdf:Description>
  <rdf:Description rdf:about="local:00002">
    <rdfs:label>Alan J. Green</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00002">
    <foaf:name>Alan J. Green</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex">
    <dc:creator rdf:resource="local:00002">local:00002</dc:creator>
  </rdf:Description>
  <rdf:Description rdf:about="local:00003">
    <rdfs:label>R. Barbara Pedley</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00003">
    <foaf:name>R. Barbara Pedley</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex">
    <dc:creator rdf:resource="local:00003">local:00003</dc:creator>
  </rdf:Description>
  <rdf:Description rdf:about="local:00004">
    <rdfs:label>Geoffrey M. Boxer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00004">
    <foaf:name>Geoffrey M. Boxer</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex">
    <dc:creator rdf:resource="local:00004">local:00004</dc:creator>
  </rdf:Description>
  <rdf:Description rdf:about="local:00005">
    <rdfs:label>Jason Dearling</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00005">
    <foaf:name>Jason Dearling</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex">
    <dc:creator rdf:resource="local:00005">local:00005</dc:creator>
  </rdf:Description>
  <rdf:Description rdf:about="local:00006">
    <rdfs:label>Rebecca Watson</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00006">
    <foaf:name>Rebecca Watson</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex">
    <dc:creator rdf:resource="local:00006">local:00006</dc:creator>
  </rdf:Description>
  <rdf:Description rdf:about="local:00007">
    <rdfs:label>Robert Boden</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00007">
    <foaf:name>Robert Boden</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex">
    <dc:creator rdf:resource="local:00007">local:00007</dc:creator>
  </rdf:Description>
  <rdf:Description rdf:about="local:00008">
    <rdfs:label>Richard H. J. Begent</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00008">
    <foaf:name>Richard H. J. Begent</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex">
    <dc:creator rdf:resource="local:00008">local:00008</dc:creator>
  </rdf:Description>
  <rdf:Description rdf:about="local:00009">
    <rdfs:label>Catherine Lloyd</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00009">
    <foaf:name>Catherine Lloyd</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex">
    <dc:contributor rdf:resource="local:00009">local:00009</dc:contributor>
  </rdf:Description>
  <rdf:Description rdf:about="local:00010">
    <dc:identifier rdf:resource="http://identifiers.org/orcid:0000-0001-5801-5510">http://identifiers.org/orcid:0000-0001-5801-5510</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00010">
    <rdfs:label>Bilal Shaikh</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00010">
    <foaf:accountName rdf:resource="https://orcid.org/0000-0001-5801-5510">https://orcid.org/0000-0001-5801-5510</foaf:accountName>
  </rdf:Description>
  <rdf:Description rdf:about="local:00010">
    <foaf:name>Bilal Shaikh</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex">
    <dc:contributor rdf:resource="local:00010">local:00010</dc:contributor>
  </rdf:Description>
  <rdf:Description rdf:about="local:00011">
    <dc:identifier rdf:resource="https://identifiers.org/pmr:8665fb9b47446f6078ed11c8cb6dd09d">https://identifiers.org/pmr:8665fb9b47446f6078ed11c8cb6dd09d</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00011">
    <rdfs:label>PMR: 8665fb9b47446f6078ed11c8cb6dd09d</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex">
    <bqmodel:is rdf:resource="local:00011">local:00011</bqmodel:is>
  </rdf:Description>
  <rdf:Description rdf:about="local:00012">
    <dc:identifier rdf:resource="https://identifiers.org/doi/10.1002/cncr.10293">https://identifiers.org/doi/10.1002/cncr.10293</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00012">
    <rdfs:label>Aiden A. Flynn, Alan J. Green, R. Barbara Pedley, Geoffrey M. Boxer, Jason Dearling, Rebecca Watson, Robert Boden &amp; Richard H. J. Begent. A model-based approach for the optimization of radioimmunotherapy through antibody design and radionuclide selection. Cancer 94, 4 Suppl: 1249-1257 (2002).</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex">
    <bqmodel:isDescribedBy rdf:resource="local:00012">local:00012</bqmodel:isDescribedBy>
  </rdf:Description>
  <rdf:Description rdf:about="local:00013">
    <dc:identifier rdf:resource="https://creativecommons.org/licenses/by/3.0/">https://creativecommons.org/licenses/by/3.0/</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00013">
    <rdfs:label>CC BY 3.0</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex">
    <dc:license rdf:resource="local:00013">local:00013</dc:license>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex">
    <dc:created>2006-07-08T15:35:17</dc:created>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex">
    <dc:modified>2006-07-08T15:35:17</dc:modified>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex/flynn_green_pedley_boxer_dearling_watson_boden_begent_2002.cellml">
    <dc:title>A Model-Based Approach for the Optimization of Radioimmunotherapy through Antibody Design and Radionuclide Selection</dc:title>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex/flynn_green_pedley_boxer_dearling_watson_boden_begent_2002.cellml">
    <dc:description>#### Model Status



 This is the original unchecked version of the model imported from the previous
 CellML model repository, 24-Jan-2006.
 


#### Model Structure



Radioimmunotherapy (RIT) is a treatment for cancer which combines radiation and immune therapy using monoclonal antibodies. RIT uses a radioactive material attached to specially designed antibodies to locate cancer within the body. Antibodies are defense proteins which are naturally produced by the body's immune system in order to fight infections caused by bacteria and other foreign pathogens. The antibodies used in RIT are monoclonal antibodies (MAbs) which are developed in the laboratory in order to recognise marker molecules on the surface of tumor cells. These antibodies are then modified to bind the radioactive metal Yttrium-90, which delivers high levels of local radiation to the tumour and subsequently destroys it.




The effectiveness of RIT is known to depend on at least six factors, including:



* the totla absorbed dose and pattern of delivery;
* radiosensitivity;
* rate of repair of sublethal damage;
* ongoing cancer proliferation during treatment;
* tumour heterogeneity; and
* tumour size.



Therefore no single parameter is a good indicator of how effective the RIT has been. Instead, several factors have to be simulataneously considered in order to get a more accurate characterisation of the biological effect.




The aim of this study by Flynn *et al.* was to develop a mathematical model that would relate the absorbed dose and its pattern of delivery to tumour response by incorporating information on each of the six influencing factors (see 
 the figure
 below). The mathemtical model was then used to optimise therapeutic efficacy in mice by matching the antibody and radionuclide characteristics while ensuring recoverable marrow toxicity. 




The complete original paper reference is cited below:




[A Model-Based Approach for the Optimization of Radioimmunotherapy through Antibody Design and Radionuclide Selection](http://www3.interscience.wiley.com/cgi-bin/abstract/90511815/ABSTRACT), Aiden A. Flynn, Alan J. Green, R. Barbara Pedley, Geoffrey M. Boxer, Jason Dearling, Rebecca Watson, Robert Boden, and Richard H. J. Begent, 2002, [*Cancer*](http://www3.interscience.wiley.com/cgi-bin/jhome/28741), 94, 1249-1257. ([Full text (HTML)](http://www3.interscience.wiley.com/cgi-bin/fulltext/90511815/HTMLSTART) and [PDF](http://www3.interscience.wiley.com/cgi-bin/fulltext/90511815/PDFSTART) versions of the article are available to subscribers on the *Cancer* website.) [PubMed ID: 11877753](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11877753&amp;dopt=Abstract)</dc:description>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex/flynn_green_pedley_boxer_dearling_watson_boden_begent_2002.cellml">
    <collex:thumbnail rdf:resource="http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex/flynn_2002.png">http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex/flynn_2002.png</collex:thumbnail>
  </rdf:Description>
  <rdf:Description rdf:about="local:00014">
    <dc:identifier rdf:resource="https://creativecommons.org/licenses/by/3.0/">https://creativecommons.org/licenses/by/3.0/</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00014">
    <rdfs:label>CC BY 3.0</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/8665fb9b47446f6078ed11c8cb6dd09d.omex/flynn_green_pedley_boxer_dearling_watson_boden_begent_2002.cellml">
    <dc:license rdf:resource="local:00014">local:00014</dc:license>
  </rdf:Description>
</rdf:RDF>
